UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
—————————————
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 6, 2010
______________________________
WORLD HEART CORPORATION
(Exact name of registrant as specified in charter)
| Delaware | | 000-28882 | | 52-2247240 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| 4750 Wiley Post Way, Suite 120, Salt Lake City, UT | | | | 84116 |
| (Address of principal executive offices) | | | | (Zip Code) |
(801) 355-6255
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
______________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On December 6, 2010, World Heart Corporation announced that an investigator-initiated study that includes patients who had received the Levacor ventricular assist device (VAD) was the subject of a presentation in the Emerging New Technologies Section at the Fifth European Mechanical Circulatory Support Summit. Preliminary clinical data suggests that the Levacor VAD does not cause acquired von Willebrand Factor (vWF) deficiency, a condition that is linked to serious bleeding disorders and that has been associated with the use of current VADs.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit 99.1 | | Press Release dated December 6, 2010 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Date: December 6, 2010 | | |
| | | |
| | | WORLD HEART CORPORATION |
| | | |
| | By: | /s/ Morgan R. Brown |
| | Name: | Morgan R. Brown |
| | Title: | Executive Vice President and Chief Financial Officer |
